Raku Co., Ltd

4154

KYG527551082

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13.25 ^TWD	-1.12%		0.00%	-13.11%

Mar. 13	Raku Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 31	Raku Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

An unknown buyer acquired TRN Marketing (M) Sdn Bhd from Raku Co., Ltd for $0.1 million.

July 16, 2023

An unknown buyer acquired TRN Marketing (M) Sdn Bhd from Raku Co., Ltd (TPEX:4154) for $0.1 million on July 17, 2023.

An unknown buyer completed the acquisition of TRN Marketing (M) Sdn Bhd from Raku Co., Ltd (TPEX:4154) on July 17, 2023.

Latest news about Raku Co., Ltd

Raku Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Raku Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	Jan. 31	CI
Raku Co., Ltd. Announces to Establish Three New Subsidiaries	Jan. 30	CI
Luxe Metal Tek Co., Ltd. announced that it expects to receive funding from Raku Co., Ltd	Jan. 29	CI
Polo Co., Ltd. announced that it expects to receive funding from Raku Co., Ltd	Jan. 29	CI
Luxe Thailand Co., Ltd. announced a financing transaction	Jan. 29	CI
True Co., Ltd. announced that it expects to receive funding from Raku Co., Ltd	Jan. 29	CI
Raku Co., Ltd. Announces Change of Representative of Juristic-Person Directors	Jan. 10	CI
Raku Co., Ltd Appoints Chen, Ming-Hao as Juristic-Person Director	23-10-03	CI
Raku Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Raku Co., Ltd Announces the Resignation of Chang, Nai-Wen as Representative Juristic-Person Director	23-08-31	CI
Raku Co., Ltd Announces Change of Chairperson	23-08-31	CI
Raku Co., Ltd announced that it has received TWD 66.18 million in funding	23-08-30	CI
Raku Co., Ltd Announces Remuneration Committee Changes	23-07-17	CI
An unknown buyer acquired TRN Marketing (M) Sdn Bhd from Raku Co., Ltd for $0.1 million.	23-07-16	CI
Raku Co., Ltd Announces Tenure Expiration of Members of Remuneration Committee	23-06-21	CI
Raku Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-13	CI
Raku Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Raku Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13	CI
Raku Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Raku Co., Ltd Announces Change of Representative by A Juristic Person Director	22-08-09	CI
Raku Co., Ltd Announces Dismissal of the Chiu, Chen-Shun as Institutional Director	22-08-08	CI
Raku Co., Ltd Appoints Wen-Chien Chang as Corporate Governance Officer	22-05-12	CI
Raku Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Raku Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI

Chart Raku Co., Ltd

Duration

Period

More charts

Company Profile

Raku Co Ltd, formerly Kino Biotech Co., Ltd., is a Singapore-based company. The Company is an integrated bio-nutraceutical and cosmeceutical company. The Company is focused on product conceptualization, development, commercialization, brand marketing, sale and distribution of healthcare and beauty products. The Company provides healthcare and beauty products and services through brands, including Kinohimitsu, Activa and Xpertise. It has over two logistic and distribution centers in Malaysia and China. The Company provides products to China, Singapore, Malaysia, Vietnam, Thailand and Indonesia.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RAKU CO., LTD	-13.11%	14.51M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B